CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc. (“SomaLogic” or the “Company”), a leader in AI-data driven proteomics technology, today announced that with the approach of the business combination closing, the Company expects projected financial results to be above the previous projections disclosed on March 29, 2021.
Sign up to receive our news releases
More SomaLogic News
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers.
SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of 2021 Revenue Growth
CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the registration statement for their business combination has been declared effective by the US Securities Exchange Commission (“SEC”), with a CM Life Sciences II special meeting date set for August 31, 2021 for shareholders of record as of July 2, 2021 and the transaction expected to close promptly thereafter.
CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI data-driven proteomics technology, today announced that Melody Harris, President and Chief Operating Officer has been named a 2021 C-Suite Award winner by the Denver Business Journal.
NEW YORK & BOULDER, Colo. (August 2, 2021)—CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI-data driven proteomics technology, today announced the
Proteomic Discoveries in Dementia and Kidney Disease: Harnessing 135 million measurements and 30 years of follow-up
Register Now | July 27th 2021 11am EST ABSTRACT The NIH-funded Atherosclerosis Risk in Communities (ARIC) Study, which began in 1987, is a treasure trove
Our presentation at the virtual 2021 Global Nash Congress features Dr. Stephen Williams , who discusses SomaLogics development of serum proteomic tests for liver biopsy components and diagnosis of at-risk NASH. Watch now to learn how these tests can help streamline clinical trials.
CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a leader in proteomics technology, announced today that Beth Israel Deaconess Medical Center’s (BIDMC) Genomics, Proteomics, Bioinformatics, and Systems Biology Center in Boston, Mass. will be the first site to offer the 7,000-plex SomaScan® Assay kits in their core lab and provide SomaScan data to their clients.
Ixaka Ltd and SomaLogic today announced a research collaboration to support the development of aptamer-based bispecific therapeutics as new anticancer agents that can recruit cytotoxic T cells and induce killing of tumor cells.